TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05915728
Drug: Gadoterate meglumine
Normalized name: Gadoterate meglumine
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT04938011
Drug: progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
Study: NCT05915728
Drug: Gadoteridol
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT05643417
Drug: HAIC、Bevacizumab、Camrelizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
Study: NCT00478998
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00854841
Drug: Dasatinib and Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted.
Study: NCT05529784
Drug: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab 300mg in pre-filled injector Q2W
Study: NCT04903847
Drug: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
Normalized name: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two-drug therapy
Study: NCT04903847
Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
Normalized name: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-drug therapy
Study: NCT06039592
Drug: Captopril Tablets
Normalized name: Captopril Tablets
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3mg/kg, tid
Study: NCT06039592
Drug: Metoprolol Oral Tablet
Normalized name: metoprolol Oral Tablet
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2mg/kg, bid
Study: NCT06039592
Drug: Torsemide Tablets
Normalized name: Torsemide Tablets
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2-0.5mg/mg, bid
Study: NCT06039592
Drug: Potassium citrate powder
Normalized name: citric acid / potassium citrate Powder for Oral Solution
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.06g/kg, tid
Study: NCT04529265
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative infusion of 2mg/kg MB after induction of anesthesia and 1mg/kg MB at the end of surgery
Study: NCT04919096
Drug: SCB-420
Normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomised to SCB-420 arm will receive a total of 3 doses of SCB-420 as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
Study: NCT04919096
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects randomised to Aflibercept arm will receive a total of 3 doses of Aflibercept as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
Study: NCT04978818
Drug: Vaxelis
Normalized name: Vaxelis
DrugBank: Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (DB10342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible infants will be block randomized to one of two study arms.
Study: NCT04978818
Drug: PedvaxHIB
Normalized name: PedvaxHIB
DrugBank: Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (DB10342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible infants will be block randomized to one of two study arms.
Study: NCT06413017
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimtuzumab：400mg,i.v.,once a week,until tumor progression、Death or untalerable toxicity
Study: NCT06413017
Drug: ICIs(Immune checkpoint inhibitors)
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use it as it is describe in the instructions from the specification
Study: NCT05942352
Drug: Ligustrazine by intravenously administration
Normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days
Study: NCT05942352
Drug: Ligustrazine by mouth
Normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Ligustrazine tablet by mouth would be maintained for 1 year
Study: NCT06543550
Drug: Implantable gestrinone
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6mg/kg of weight of gestrinone in pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region.
Study: NCT06543550
Drug: Oral Dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally at 2 mg daily
Study: NCT06133114
Drug: Clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg twice a day (1 mg a day)
Study: NCT06133114
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg once a day of Olanzapine
Study: NCT06133114
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 mg once a day of Buprenorphine
Study: NCT05244811
Drug: Combined Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: effect of cocs in treatment of ovarian cysts
Study: NCT02154347
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06145958
Drug: Luteinising Hormone-Releasing Factor Analogue
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Androgen Deprivation Therapy
Study: NCT05019534
Drug: Vemurafenib Oral Tablet [Zelboraf]
Normalized name: vemurafenib Oral Tablet [Zelboraf]
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960mg qd or 960mg bid (2 cohorts)
Study: NCT05019534
Drug: Cetuximab Injection [Erbitux]
Normalized name: cetuximab Injection [Erbitux]
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500mg/m2 Q2W
Study: NCT05019534
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg Q2W
Study: NCT06217003
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative application of trilaciclib during perioperative chemotherapy
Study: NCT05885919
Drug: Edaravone Dexborneol Concentrated Solution for injection
Normalized name: edaravone Injection
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
Study: NCT05885919
Drug: Edaravone Dexborneol placebo
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
Study: NCT05016544
Drug: inetetamab
Normalized name: Inetetamab
DrugBank: Inetetamab (DB17457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
Study: NCT05016544
Drug: Pytotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting pytotinib Dose of 240mg:~Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w.
Study: NCT00166686
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05852028
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: this is a real-world. Patients who use selinexor-based regimens in lymphoma will be followed up without interfering with the choice of treatment options for patients
Study: NCT04957940
Drug: SMOFlipid
Normalized name: Smoflipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fish-oil-based lipid (SMOF lipid 20%) (Fresenius Kabi, Bad Homburg, Germany) emulsion supplementation to standard enteral nutrition in a dose of 100 ml/day at a rate of 12.5 ml/h over 8 h daily for 5 days.
Study: NCT06414512
Drug: Flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed.
Study: NCT06539975
Drug: Evening Primrose Oil 1000 MG
Normalized name: evening primrose oil 1000 MG
DrugBank: Evening primrose oil (DB11358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil 1000mg vaginally plus misoprostal for induction of labor
Study: NCT05646199
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive metformin
Study: NCT05646199
Drug: Semaglutide Injectable Product
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in this group will receive injectable Semaglutide
Study: NCT00410787
Drug: OROS hydromorphone HCI (slow release)
Normalized name: Slow-Fe
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05902221
Drug: amoxicillin or moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic treatment back bone during 12 weeks
Study: NCT05902221
Drug: amoxicillin or moxifloxacin + rifampicin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic treatment back bone during 12 weeks + rifampicin
Study: NCT04930237
Drug: Docusate Calcium
Normalized name: Docusate Calcium
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT04930237
Drug: Bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT04930237
Drug: Milk of magnesia
Normalized name: MILK OF MAGNESIA
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT04930237
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of Care
Study: NCT04930237
Drug: Senna
Normalized name: Senna
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT04930237
Drug: Enema
Normalized name: Enema
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT05466539
Drug: AbobotulinumtoxinA
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Participants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging.
Study: NCT05360030
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
Study: NCT05360030
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
Study: NCT05360030
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
Study: NCT00655252
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000664
Drug: Interleukin-2, Polyethylene Glycolated
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000664
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05291182
Drug: SY-4835
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WEE1 inhibitor
Study: NCT05760976
Drug: Cisatracurium
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Advanced intravenous injection of cisatracurium before the succinylcholine injection
Study: NCT05297890
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage Form: Lorlatinib tablet, Dosage: 25mg/tablet, Dosing Regimens: 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
Study: NCT05996952
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated with RC48-ADC at 2.0 mg/kg as an intravenous infusion over 30-90 minutes (60 minutes is recommended) once every 2 weeks for 12 weeks.
Study: NCT05816382
Drug: TAK-861
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-861 tablets
Study: NCT05583214
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia
Study: NCT05583214
Drug: Dexamethasone 8mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia
Study: NCT04986735
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects will have a baseline assessment and be prospectively followed up for 52 weeks to examine their outcome after receiving empagliflozin for neutropenia and neutrophil dysfunction.
Study: NCT04905108
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of riboflavin one drop every 2 minutes during UVA exposure
Study: NCT04905108
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of riboflavin one drop every 10 minutes during UVA exposure
Study: NCT05254899
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg iv on Day 1 of each 14-day cycle for 3 cycles in induction treatment; 200mg iv on Day 1,15, 29 during RT treatment
Study: NCT05254899
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3000 U/m2 im on Day 2 of each 14-day cycle for 3 cycles in induction treatment
Study: NCT05254899
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
Study: NCT05254899
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
Study: NCT04692376
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.
Study: NCT05611853
Drug: BN301
Normalized name: Bempedoic Acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.
Study: NCT05550597
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution
Study: NCT05084599
Drug: Metaraminol 2.7μg/kg/min
DrugBank: Metaraminol (DB00610)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
Study: NCT05084599
Drug: Metaraminol 2μg/kg/min
DrugBank: Metaraminol (DB00610)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.
Study: NCT04791202
Drug: Dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm descriptions
Study: NCT05411874
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 5mg po biw for 24 weeks
Study: NCT04699357
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children
Study: NCT06178757
Drug: TAPB
Normalized name: Treprostinil Acetate Phosphate Buccal
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As soon as the surgical procedure is completed, TAPB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed at the level of the anterior axillary line between the 12th rib and the iliac crest, and the external oblique abdominal muscle, internal oblique abdominal muscle, and transverse abdominis muscle will be visualized. Then, using the in-plane technique, the needle will be advanced with the help of ultrasound until the needle tip reaches the space between the internal oblique and transversus abdominis muscles. After negative pressure aspiration, 5ml saline will be injected and the block location will be confirmed. Once the block location is confirmed, 20ml 0.25% bupivacaine (40ml total for each side) will be injected bilaterally.
Study: NCT06624943
Drug: biosimilar insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily injection of biosimilar insulin glargine via reusable pen
Study: NCT06332300
Drug: Adebelimumab+Famitinib + FOLFIRI+Ariely
Normalized name: Axitinib
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy
Study: NCT05694936
Drug: Sodium Valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL); Refer to arm description.
Study: NCT05694936
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
Study: NCT05694936
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
Study: NCT04787289
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
Study: NCT06612814
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parp inhibitor
Study: NCT06612814
Drug: Dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitor